CROE

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Jeffing E Russel Art Unit: 657 Phone Number 30 8-5775	Examiner #: 62-785 Date: 10-15-2002
Art Unit: 1654 Phone Number 30 8 - 3 975	Serial Number: 09/808.832
Mail Box and Bldg/Room Location: Resul	Its Format Preferred (circle): PAPER DISK E-MAIL
If more than one search is submitted, please prioritize	
Please provide a detailed statement of the search topic, and describe a	
Include the elected species or structures, keywords, synonyms, acrony	ms, and registry numbers, and combine with the concept or
utility of the invention. Define any terms that may have a special mea	•
known. Please attach a copy of the cover sheet, pertinent claims, and a	
Title of Invention: Rept dese - cleaveble targeted as	
Inventors (please provide full names): R Copela & C. Alb	right A. Conbs, R. Douling N. Graciani
W. Han, C. Highey, P. Huang, E. Yve, S.	Dimeo
Earliest Priority Filing Date: 3-13-2001	
*For Sequence Searches Only * Please include all pertinent information (p	arent, child, divisional, or issued patent numbers) along with the
applopriale serial number.	
Place see- & SEO IONO. 186 (VOL ZVVII)
· · · · · · · · · · · · · · · · · · ·	•
in the U.J. patest effication so	quera databese (issued apending)
	3 3 61
and in Genesoy Subsynt/PIR. P	lesse require any Little to have
10 or fewer residues	i .
	Point of Contact:
	Mona Smith Technical Information Specialist CM1 6A01
A Secretary of the second second second	CMI KANA """ ODGERNIE
red of the first of the second	Tel: 308-1778
	y)
I was to be a second of the second of the	
Contract to the second	
	by the second se
	and the same of th
	So co to
	Sales of the sales
	Sales of the sales
	Sales of the sales
STAFF USE ONLY Type of Search	Vendors and cost where applicable
STAFFUSE ONLY Type of Search NA Sequence (#)	Vendors and cost where applicable
Searcher: 10 Say 174 NA Sequence (#)	STN
Searcher: M. S. NA Sequence (#) Searcher Phone #: AA Sequence (#)	- STN
Searcher: No. Su 174 NA Sequence (#) Searcher Phone #: AA Sequence (#) Searcher Location: Structure (#)	STN Dialog Questel/Orbit
Searcher: No. Sur 174 NA Sequence (#) Searcher Phone #: AA Sequence (#) Searcher Location: Structure (#) Date Searcher Picked Up: 10 18 02 Bibliographic	STN
NA Sequence (#) NA Sequenc	STN Dislog Questel/Orbit Dr.Link Lexis/Nexis
Searcher Phone #: Searcher Phone #: Searcher Location: Date Searcher Picked Up: Date Completed: Date Completed: Date Review Time: Date Searcher Prep & Review Time: Date Searcher Prep	Ouestel/Orbit Dr.Link Lexis/Nexis Sequence Systems
Searcher: M. Surit NA Sequence (#) Searcher Phone #: AA Sequence (#) Searcher Location: Structure (#) Date Searcher Picked Up: 10 18 02 Bibliographic Date Completed: 10 24 0 2 Litigation Searcher Prep & Review Time: 10 Fulltext Clerical Prep Time: Patent Family	STN Dislog Questel/Orbit Dr.Link Lexis/Nexis Sequence Systems WWW/Internet

Russel 09/808,832Page 1

=> fil hcaplu
FILE 'HCAPLUS' ENTERED AT 13:09:09 ON 23 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Oct 2002 VOL 137 ISS 17 FILE LAST UPDATED: 22 Oct 2002 (20021022/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d stat que

INVENTOR(S):

L1 4 SEA FILE=REGISTRY XPLGXYL/SQSP L2 371099 SEA FILE=REGISTRY SQL=<10 L3 4 SEA FILE=REGISTRY L1 AND L2

L4 1 SEA FILE=HCAPLUS L3

=> d ibib abs hitrn 14

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:693138 HCAPLUS

DOCUMENT NUMBER: 135:273218

TITLE: Preparation of peptidase-cleavable, targeted

antineoplastic drugs and their therapeutic use Copeland, Robert A.; Albright, Charles F.; Combs, Andrew P.; Dowling, Radine L.; Graciani, Nilsa R.;

Han, Wei; Higley, C. Anne; Huang, Pearl S.; Yue, Eddy

W.; Dimeo, Susan V.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 203 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE _____ WO 2001068145 A2 20010920 WO 2001-US8589 20010315 A3 20020711 WO 2001068145 W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IN, JP, KR, LT, LU, LV, MX, NZ, PL, PT, RO, RU, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR 20020801 US 2001-808832 US 2002103133 Al 20010315 PRIORITY APPLN. INFO.: US 2000-189387P P 20000315 OTHER SOURCE(S): MARPAT 135:273218 This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase. The conjugated compds. are for use as chemotherapeutic agents in the targeted treatment of cancers. Claimed peptide sequences include Cap-Paa-Xa2-Gly-Xp1-Laa, where Cap is an N-terminus group R, Xa4 or R-Xa4 (R is an amino capping group, Xa4 is an amino acid), Paa is Pro, 4-hydroxyproline (Hyp), 2-carboxyazetidine (Aze), homo-Pro, cyclohexylglycine (Chg), 4-fluorophenylalanine (Fph), nipecotic acid (Npa), 4thiazolidinecarboxylic acid (Tzc), or proline mimetic; Xa2 is an amino acid; Xp1 is is an amino acid wherein -Gly-Xp1- or -Sar-Xp1 form a bond cleavable by a matrixin; Laa is an amino acid, e.g., Leu, Ile, Nle, .beta.-homo-Leu, homoleucine, homoserine, Ala and cyclohexylalanine. Thus, peptide conjugate Ac-PLGLYL-Dox (Dox = doxorubicin) was prepd. by the solid phase method and evaluated for stability in blood and cleavage with MMPs and neprilysin. 360780-48-9P IT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of antineoplastic agents conjugated to enzyme-cleavable peptides) 362675-79-4 362676-88-8 362677-10-9 IT RL: PRP (Properties) (unclaimed protein sequence; prepn. of peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use)

FILE 'REGISTRY' ENTERED AT 13:09:34 ON 23 OCT 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

22 OCT 2002 HIGHEST RN 464152-74-7 STRUCTURE FILE UPDATES: DICTIONARY FILE UPDATES: 22 OCT 2002 HIGHEST RN 464152-74-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Russel 09/808,832Page 3

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s 14 L5 4 L3

=> d rn cn lc nte sql kwic can tot 15

L5 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2002 ACS

RN 362677-10-9 REGISTRY

CN 185: PN: WOO168145 SEQID: 186 unclaimed protein (9CI) (CA INDEX NAME)

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

NTE

type ----- location ----- description
-----uncommon Aaa-1 - -

uncommonAaa-1~~uncommonAaa-5~~

SQL 7

SEQ 1 XPLGXYL

HITS AT: 1-7

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 135:273218

L5 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2002 ACS

RN 362676-88-8 REGISTRY

CN 175: PN: WO0168145 SEQID: 176 unclaimed protein (9CI) (CA INDEX NAME)

C STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

NTE

type ----- location ----- description

uncommon Aaa-1 - -

uncommon Aaa-5 - -

SQL 7

SEQ 1 XPLGXYL

HITS AT: 1-7

Russel 09/808,832Page 4

```
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
REFERENCE 1: 135:273218
   ANSWER 3 OF 4 REGISTRY COPYRIGHT 2002 ACS
L5
   362675-79-4 REGISTRY
RN
CN 104: PN: W00168145 SEQID: 105 unclaimed protein (9CI) (CA INDEX NAME)
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
______
           ----- location -----
                                 description
uncommon Aaa~1
uncommon Aaa~5
______
SQL 7
SQL 7
SEQ
      1 XPLGXYL
       ======
HITS AT: 1-7
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
REFERENCE 1: 135:273218
  ANSWER 4 OF 4 REGISTRY COPYRIGHT 2002 ACS
L5
   360780-48-9 REGISTRY
   5,12-Naphthacenedione, 10-[[3-[(N-acetyl-L-.gamma.-glutamyl-L-prolyl-L-
   leucylglycyl-.alpha.-aminobenzenebutanoyl-L-tyrosyl-L-leucyl)amino]-2,3,6-
   trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-
   trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (85,105)- (9CI) (CA INDEX NAME)
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
NTE modified (modifications unspecified)
______
           ----- location ----- description
uncommon Ggu-1
uncommon Aaa-5
_____
SQL 7
SQL 7
SEO
      1 XPLGXYL
       ======
HITS AT: 1-7
REFERENCE 1: 135:273218
```

OM protein - protein search, using sw model

Run on: October 23, 2002, 13:41:42; Search time 30 Seconds

(without alignments)

25.917 Million cell updates/sec

Title: US-09-808-832-186

Perfect score: 30

Sequence: 1 XPLGXYL 7

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 135323

Minimum DB seq length: 0 Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100% Listing first 45 summaries

Database: A Geneseq 032802:*

1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*

2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*

3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*

4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*

5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*

6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*

7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*

8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*

9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*

10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*

11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*

12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*

13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*

14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*

15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*

- 16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
- 17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
- 18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
- 19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
- 20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
- 21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
- 22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

~/n

	/	U		
Result		Query		
No.	Scor	re Mat	ch Length DB ID	Description
1	23	76.7	6 22 AAU07722	Human matrix type-
2	23	76.7	8 19 AAW52141	Matrix metalloprot
3	23	76.7	8 22 AAB97518	Substituted phosph
4	23	76.7	10 21 AAB51837	Human secreted pro
5	23	76.7	10 22 AAB97519	Substituted phosph
6	22	73.3	9 20 AAY48081	Immunogenic peptid
7	21	70.0	8 19 AAW54885	Isozyme-specific a
8	21	70.0	9 20 AAY48098	Immunogenic peptid
9	21	70.0	9 22 AAU06336	Human Leukocyte An
10	21	70.0	10 20 AAY46811	Immunogenic peptid
11	20	66.7	10 22 AAG96570	Human complementar
12	19	63.3	6 18 AAW28950	Opioid peptide. S
13	19	63.3	6 18 AAW24311	New peptide which
14	19	63.3	6 20 AAY23060	Opioid peptide whi
15	19	63.3	7 6 AAP50083	Thiopeptolide havi
16	19	63.3	8 20 AAW89344	Peptide SEQ ID NO:
17	19	63.3	10 15 AAR61665	Peptide fragment (
18	18	60.0	6 21 AAB37325	Peptide linker #10
19	18	60.0	6 21 AAB15681	Matrix metalloprot
20	18	60.0	6 21 AAB22834	Matrix metalloprot
21	18	60.0	6 21 AAB01558	Collagenase substr
22	18	60.0	6 22 AAU07359	Metalloproteinase
23	18	60.0	6 22 AAB67721	Amino acid sequenc
24	18	60.0	6 22 AAB67722	Amino acid sequenc
25	18	60.0	6 22 AAB73911	MMP-2 protease cle
26	18	60.0	6 22 AAB73912	MT1-MMP protease c
27	18	60.0	6 22 AAB35976	Collagenase cleava
28	18	60.0	7 15 AAR67143	Enkephalin derived

29	18	60.0	7 17	AAR87156	Variant bovine gro
30	18	60.0	7 18	AAW24983	Recombinant human
31	18	60.0	7 22	AAG65041	Human matrix metal
32	18	60,0	7 22	AAB75135	Gelatinase recogni
33	18	60.0	7 22	AAB74039	Synthetic collagen
34	18	60.0	7 22	AAB35980	Gelatinase cleavab
35	18	60.0	8 14	AAR35857	Hepatitis C virus
36	18	60.0	8 14	AAR35858	Hepatitis C virus
37	18	60.0	8 14	AAR35859	Hepatitis C virus
38	18	60.0	8 14	AAR35860	Hepatitis C virus
39	18	60.0	8 16	AAR73431	Human TSH receptor
40	18	60.0	8 16	AAR73432	Human TSH receptor
41	18	60.0	8 19	AAY20465	Human microtubule
42	18	60.0	8 22	AAB97545	Substituted phosph
43	18	60.0	8 22	AAB62230	MMP substrate octa
44	18	60.0	8 22	AAB86845	MMP-2 and MMP-9 bi
45	18	60.0	9 15	AAY38358	PAP-derived HLA-bi

ALIGNMENTS

```
RESULT 1
AAU07722
ID AAU07722 standard; peptide; 6 AA.
XX
AC AAU07722;
XX
DT 21-NOV-2001 (first entry)
XX
DE Human matrix type-1-metalloprotease protease cleavage site.
XX
KW Human matrix type-1-metalloprotease; MT1-MMP;
KW protease cleavage site, cytostatic, antirheumatic,
KW antirheumatic; antiarthritic; immunosuppressive; antiinflammatory;
KW anti-HIV; virucide; viral display; gene therapy; cancer; inflammation;
KW rheumatoid arthritis; autoimmune disease; infection; AIDS;
KW acquired immunodeficiency syndrome; herpes; hepatitis;
KW protease inhibitor; drug screening.
XX
OS Homo sapiens.
XX
PN WO200162980-A1.
XX
PD 30-AUG-2001.
```

```
XX
PF 23-FEB-2001; 2001WO-US05859.
XX
PR 25-FEB-2000; 2000US-0185203.
XX
PA (CAMB-) CAMBRIDGE DRUG DISCOVERY LTD.
XX
PI Russell SJ, Chadwick MP;
XX
DR WPI; 2001-541706/60.
XX
PT Identifying protease inhibitors by assaying for the presence of a
PT transferable label from a viral display package in the presence of test
PT compound, where an increase in cell label indicates the compound as a
PT protease inhibitor -
XX
PS Example 1; Page 20; 46pp; English.
XX
CC The invention relates to identifying a test substance for the ability to
CC inhibit a protease by contacting a protease-containing target cell with a
CC viral display package (comprising a receptor-binding polypeptide which
CC binds to a receptor on the surface of the cell, a protease cleavage site
CC for the protease expressed by the cell, and a fusion-mediating
CC polypeptide, such that proteolytic cleavage of the cleavage site does not
CC permit substantial transfer of the transferable label from the phage
CC package to the cell), and detecting a transferable label to indicate if
CC the substance is a protease inhibitor. The method is useful for
CC identifying a test substance for its ability to inhibit a protease. The
CC delivery of an expressible polynucleotide to a target cell is also
CC possible, and both methods are applicable for a number of target cells.
CC The methods are useful for therapeutic purposes and as a model system for
CC optimising delivery of transferable labels. The protease inhibitors
CC identified are useful for treating cancer, inflammation, rheumatoid
CC arthritis, autoimmune diseases, infections including AIDS (acquired
CC immunodeficiency syndrome), herpes and hepatitis. A whole range of
CC proteins, peptides, antisense transcripts and ribozyme sequences can be
CC encoded within an expressible polynucleotide (i.e. a gene therapy
CC technique) and delivered to a target cell for a therapeutic effect. The
CC target cells may also be cells infected by pathogens such as HIV virus,
CC rhinovirus, herpes virus, hepatitis virus or other infectious agents
CC which expresses proteases. The present sequence is a human matrix type-1-
CC metalloprotease (MT1-MMP) protease cleavage site which may be used as a
CC component of the viral display package used in the method of the
CC invention.
```

XX

```
SQ Sequence 6 AA;
                    76.7%; Score 23; DB 22; Length 6;
 Query Match
 Best Local Similarity 80.0%; Pred. No. 6.4e+05;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy
      2 PLGXY 6
      \parallel \parallel \parallel
Db
      1 PLGLY 5
RESULT 2
AAW52141
ID AAW52141 standard; Peptide; 8 AA.
XX
AC AAW52141;
XX
DT 20-JUL-1998 (first entry)
XX
DE Matrix metalloproteinase MMP-9 substrate MR1.
XX
KW Membrane-type matrix metalloproteinase; MT-MMP; MT1-MMP;
KW matrix metalloproteinase 12; MMP-12; osteoclastic proteinase;
KW osteoclast; inhibitor; metabolic bone disease; osteoporosis;
KW bone resorption; metastasis; tumour; cancer; ulcer; arthritis;
KW periodontal disease; therapy.
XX
OS Synthetic.
XX
FH Key
               Location/Qualifiers
FT Modified-site 1
             /note= "Abz-glycine"
FT
FT Cleavage-site 4..5
FT Modified-site 6
FT
             /note= "Norleucine"
FT Modified-site 9
             /note= "tyrosine(NO2)"
FT
XX
PN WO9804287-A1.
XX
PD 05-FEB-1998.
XX
PF 29-JUL-1997; 97WO-EP04110.
XX
```

PR 30-JUL-1996; 96GB-0015976.

```
XX
PA (CLIN-) CENT CLINICAL & BASIC RES.
PI Delaisse J, Foged NT, Meldal M;
XX
DR WPI; 1998-130425/12.
XX
PT Use of inhibitors of protease(s) involved in osteoclast activity -
PT useful for, e.g. treating metabolic bone disease such as
PT osteoporosis
XX
PS Example 6b; Page 44; 110pp; English.
XX
CC Peptide MR1 is a substrate of matrix metalloproteinase MMP-9. Novel
CC peptide substrate mimicking MMP-inhibitors (see AAW52132-33) are
CC promising agents for use in treatment of bone metabolic disease.
CC They can be used to inhibit proteinases involved in the
CC recruitment, proliferation, differentiation or migration of
CC osteoclast precursor cells or in the migation, fusion, attachment,
CC polarisation, removal of mineralised osseous substance or death of
CC osteoclasts. The inhibitors reduce the rate of bone resorption
CC and are used to treat or prevent, e.g. osteoporosis and osteolytic
CC bone metastases. They are also useful in, e.g. treatment of
CC cancer, ulcers, arthritis and periodontal disease.
XX
SQ Sequence 8 AA;
                     76.7%; Score 23; DB 19; Length 8;
 Query Match
 Best Local Similarity 80.0%; Pred. No. 6.4e+05;
 Matches 4; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy
      2 PLGXY 6
      2 PLGLY 6
Db
Search completed: October 23, 2002, 13:42:22
```

Job time: 32 secs

OM protein - protein search, using sw model

Run on: October 23, 2002, 13:41:43; Search time 24 Seconds

(without alignments)

50.457 Million cell updates/sec

Title: US-09-808-832-186

Perfect score: 30

Sequence: 1 XPLGXYL 7

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 562222 seqs, 172994929 residues

Total number of hits satisfying chosen parameters: 1088

Minimum DB seq length: 0 Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100% Listing first 45 summaries

Database: SPTREMBL_19:*

1: sp_archea:*

2: sp bacteria:*

3: sp_fungi:*

4: sp human:*

5: sp_invertebrate:*

6: sp_mammal:*

7: sp_mhc:*

8: sp organelle:*

9: sp phage:*

10: sp_plant:*

11: sp_rodent:*

12: sp_virus:*

13: sp_vertebrate:*

14: sp_unclassified:*

15: sp_rvirus:*

16: sp_bacteriap:*
17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

% Result Query No. Score Match Length DB ID Description 17 56.7 Q9s905 glycine max 1 10 10 Q9S905 2 16 53.3 8 12 Q89498 Q89498 murine hepa 3 15 50.0 10 10 Q94IS6 Q94is6 pinus taeda 4 14 46.7 8 12 Q83349 Q83349 murine coro 5 13 43.3 8 4 Q9P0K3 Q9p0k3 homo sapien 6 13 43.3 9 11 Q9QWT0 Q9qwt0 mus musculu 7 13 43.3 10 4 060912 O60912 homo sapien 8 12 40.0 8 2 Q9RQ49 Q9rq49 buchnera ap 9 12 40.0 8 4 Q96RN9 Q96rn9 homo sapien 10 12 40.0 8 8 P92422 P92422 psathyrosta 11 12 40.0 8 8 P92373 P92373 haynaldia v 12 12 40.0 8 8 P93985 P93985 aegilops co 13 40.0 8 8 P92404 P92404 lophopyrum 12 14 12 40.0 8 8 P92426 P92426 pseudoroegn 15 12 40.0 8 8 P93973 P93973 eremopyrum 40.0 8 8 P93970 16 12 P93970 eremopyrum 17 12 40.0 8 8 P92388 P92388 henrardia p 18 12 40.0 8 8 P92428 P92428 peridictyon 19 12 40.0 8 8 P92391 P92391 heteranthel 20 12 40.0 8 8 P92227 P92227 crithopsis 21 12 40.0 8 8 P93963 P93963 psathyrosta 8 8 P93961 22 12 40.0 P93961 psathyrosta 23 12 40.0 8 8 P92215 P92215 amblyopyrum 24 12 40.0 8 8 P93981 P93981 crithodium 25 40.0 12 8 8 P92431 P92431 aegilops ta 26 12 40.0 8 8 P92222 P92222 bromus iner 27 12 40.0 8 8 P92443 P92443 taeniatheru 28 12 40.0 8 8 P92382 P92382 hordeum bra 29 12 40.0 8 8 P92384 P92384 hordeum mur 30 12 40.0 8 8 P92386 P92386 hordeum mar 31 12 40.0 8 8 P92394 P92394 hordeum vul 32 12 40.0 8 8 P93965 P93965 secale stri 33 12 40.0 8 8 P93966 P93966 aegilops sp

12	40.0	8 8 P92219	P92219 australopyr
12	40.0	8 8 P93992	P93992 australopyr
12	40.0	8 8 P92441	P92441 thinopyrum
12	40.0	8 8 P93955	P93955 festucopsis
12	40.0	8 8 P92211	P92211 agropyron c
12	40.0	8 8 P93959	P93959 hordeum ere
12	40.0	8 8 P93957	P93957 festucopsis
12	40.0	9 13 P83057	P83057 bombina var
12	40.0	9 13 P83056	P83056 bombina var
12	40.0	10 2 Q9AE19	Q9ae19 streptococc
12	40.0	10 4 Q9H1I5	Q9h1i5 homo sapien
12	40.0	10 4 Q14096	Q14096 homo sapien
	12 12 12 12 12 12 12 12 12 12	12 40.0 12 40.0	12 40.0 8 8 P93992 12 40.0 8 8 P92441 12 40.0 8 8 P93955 12 40.0 8 8 P92211 12 40.0 8 8 P93959 12 40.0 8 8 P93957 12 40.0 9 13 P83057 12 40.0 9 13 P83056 12 40.0 10 2 Q9AE19 12 40.0 10 4 Q9H115

```
ALIGNMENTS
RESULT 1
Q9S905
ID Q9S905
              PRELIMINARY;
                                 PRT; 10 AA.
AC Q9S905;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)
DE S3 PEPTIDE.
OS Glycine max (Soybean).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae; Glycine.
OX NCBI TaxID=3847;
RN [1]
RP SEQUENCE.
RX MEDLINE=92232221; PubMed=1368037;
RA Hirano H., Kagawa H., Okubo K.;
RL Phytochemistry 31:731-735(1992).
SQ SEQUENCE 10 AA; 975 MW; 3C733271A879D1B7 CRC64;
                   56.7%; Score 17; DB 10; Length 10;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 1.4e+03;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
     2 PLG 4
Qy
     \parallel \parallel
Db
     8 PLG 10
```

Search completed: October 23, 2002, 13:43:10

Job time: 25 secs

OM protein - protein search, using sw model

Run on: October 23, 2002, 13:41:42; Search time 10 Seconds

(without alignments)

27.104 Million cell updates/sec

Title: US-09-808-832-186

Perfect score: 30

Sequence: 1 XPLGXYL 7

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 105224 seqs, 38719550 residues

Total number of hits satisfying chosen parameters: 349

Minimum DB seq length: 0 Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: SwissProt_40:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

% Result Query No. Score Match Length DB ID Description 1 17 56.7 9 1 OXYA_SQUAC P42999 squalus aca 2 9 1 OXYT RABIT P32878 oryctolagus 17 56.7 9 1 TKL1 LOCMI 3 17 56.7 P16223 locusta mig 8 1 UF06 MOUSE 4 16 53.3 P38644 mus musculu 5 9 1 ISOT CYPCA 15 50.0 P42993 cyprinus ca

6	15 50.0	9 1 OXYT_BUFRE	P42995 bufo regula
7	15 50.0	9 1 OXYT_OCTVU	P80027 octopus vul
8	14 46.7	7 1 FAR5_HIRME	P42564 hirudo medi
9	14 46.7	9 1 OXYA_SCYCA	P42996 scyliorhinu
10	14 46.7	9 1 OXYF_SCYCA	P42997 scyliorhinu
11	14 46.7	9 1 OXYV_SQUAC	P43000 squalus aca
12	13 43.3	10 1 TKL2_LOCMI	P16224 locusta mig
13	12 40.0	8 1 AL17 CARMA	P81820 carcinus ma
14	12 40.0	9 1 AL11 CARMA	P81814 carcinus ma
15	12 40.0	9 1 NEUŪ CAVPO	P34966 cavia porce
16	12 40.0	9 1 OXYT EISFO	P42998 eisenia foe
17	12 40.0	9 1 TKC1 CALVO	P41517 calliphora
18	12 40.0	10 1 AMPN HELAM	P81731 helicoverpa
19	12 40.0	10 1 CU30_LOCMI	P11735 locusta mig
20	12 40.0	10 1 ESTA SCHGA	P81012 schizaphis
21	12 40.0	10 1 RLA2 MOUSE	P99027 mus musculu
22	12 40.0	10 1 TKL3 LOCMI	P30249 locusta mig
23	11 36.7	4 1 FAR3 HIRME	P42562 hirudo medi
24	11 36.7	5 1 PRCT PERAM	P01373 periplaneta
25	11 36.7	6 1 VP19 HSV1K	P23210 herpes simp
26	11 36.7	7 1 FAR2 ASCSU	P31890 ascaris suu
27	11 36.7	7 1 GFRP MOUSE	P99025 mus musculu
28	11 36.7	7 1 MNP1 LEPDE	P42984 leptinotars
29	11 36.7	8 1 AL15 CARMA	P81818 carcinus ma
30	11 36.7	8 1 AL16 CARMA	P81819 carcinus ma
31	11 36.7	8 1 ALL6 CYDPO	P82157 cydia pomon
32	11 36.7	8 1 ALL8 CARMA	P81811 carcinus ma
33	11 36.7	8 1 ALL9 CARMA	P81812 carcinus ma
34	11 36.7	9 1 CONO CONGE	P05486 conus geogr
35	11 36.7	9 1 CONO CONST	P05487 conus stria
36	11 36.7	9 1 DNF1 LOCMI	P16339 locusta mig
37	11 36.7	9 1 FAR9 ASCSU	P43172 ascaris suu
38	11 36.7	9 1 LITO_LITAU	P08945 litoria aur
39	11 36.7	9 1 OXYT CYPCA	P23879 cyprinus ca
40	11 36.7	9 1 OXYT RAJCL	P42994 raja clavat
41	11 36.7	9 1 TRP4 LEUMA	P81736 leucophaea
42	11 36.7	9 1 UPA3 HUMAN	P30089 homo sapien
43	11 36.7	10 1 AL19 CARMA	P81822 carcinus ma
44	11 36.7	10 1 ANG1 BOTJA	Q10581 bothrops ja
45	11 36.7	10 1 BRK ONCMY	Q9przl oncorhynchu
		- - · ·	1

```
RESULT 1
OXYA SQUAC
                                     PRT; 9 AA.
ID OXYA SQUAC
                     STANDARD;
AC P42999;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 01-NOV-1995 (Rel. 32, Last annotation update)
DE Aspartocin (Aspargtocin).
OS Squalus acanthias (Spiny dogfish).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;
OC Elasmobranchii; Squalea; Squaloidei; Squalidae; Squalus.
OX NCBI TaxID=7797;
RN [1]
RP SEQUENCE.
RX MEDLINE=73031727; PubMed=5083097;
RA Acher R., Chauvet J., Chauvet M.-T.;
RT "Phylogeny of the neurohypophysial hormones. Two new active peptides
RT isolated from a cartilaginous fish, Squalus acanthias.";
RL Eur. J. Biochem. 29:12-19(1972).
RN [2]
RP SEQUENCE.
RX MEDLINE=72128038; PubMed=4622083;
RA Acher R., Chauvet J., Chauvet M.-T., Fontaine M.;
RT "Identification of 2 new neurohypophyseal hormones, valitocin (Val8-
RT oxytocin) and aspartocin (Asn4-oxytocin) in a selachian fish, the
RT spiny dog-fish (Squalus acanthias).";
RL C. R. Acad. Sci., D, Sci. Nat. 274:313-316(1972).
CC -!- SIMILARITY: BELONGS TO THE VASOPRESSIN/OXYTOCIN FAMILY.
DR InterPro; IPR000981; Neurhypophys horm.
DR Pfam; PF00220; hormone4; 1.
DR PROSITE; PS00264; NEUROHYPOPHYS HORM; 1.
KW Hormone; Amidation.
FT DISULFID
                 1
                      6
FT MOD RES
                       9
                            AMIDATION.
SO SEQUENCE 9 AA; 996 MW; 17F8376EB444404B CRC64;
                    56.7%; Score 17; DB 1; Length 9;
 Query Match
 Best Local Similarity 100.0%; Pred. No. 1e+05;
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
     2 PLG 4
Qy
     \parallel \parallel
Db
     7 PLG 9
Search completed: October 23, 2002, 13:42:39
Job time: 12 secs
```

OM protein - protein search, using sw model

Run on: October 23, 2002, 13:41:47; Search time 14 Seconds

(without alignments)

48.045 Million cell updates/sec

Title: US-09-808-832-186

Perfect score: 30

Sequence: 1 XPLGXYL 7

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 283138 seqs, 96089334 residues

Total number of hits satisfying chosen parameters: 1099

Minimum DB seq length: 0 Maximum DB seq length: 10

Post-processing: Minimum Match 0%

Maximum Match 100% Listing first 45 summaries

Database: PIR 71:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%

Result No.	` '	ch Length DB ID	Description
1	17 56.7	4 2 A32039	tyrosine-melanocyt

2	17 56.7	8 4 154017	granulocyte-colony
3	17 56.7	9 2 A91466	oxytocin - hippopo
4	17 56.7	9 2 A92774	oxytocin - spotted
5	17 56.7	9 2 A93147	oxytocin - finback
6	17 56.7	9 2 A93408	oxytocin - Austral
7	17 56.7	9 2 B90667	oxytocin - rabbit
8	16 53.3	8 2 PT0311	Ig heavy chain CRD
9	15 50.0	8 2 PT0368	Ig gamma chain C r
10	15 50.0	9 2 A61364	isotocin - common
11	14 46.7	7 2 A11483	aspartate transami
12	13 43.3	9 2 S15850	vitamin D3 26-mono
13	13 43.3	9 2 S36850	Ig heavy chain V r
14	13 43.3	9 2 G41946	T-cell receptor ga
15	13 43.3	10 2 PT0038	glutathione transf
16	12 40.0	5 2 B61445	Leu-enkephalin - b
17	12 40.0	6 2 JN0861	peptidyl-dipeptida
18	12 40.0	8 2 PT0530	T-cell receptor be
19	12 40.0	9 2 S63491	dissimilatory sulf
20	12 40.0	9 2 S36898	ribosomal protein
21	12 40.0	9 2 PC2021	oxytocin-related p
22	12 40.0	9 2 PH1591	Ig H chain V-D-J r
23	12 40.0	10 1 ECLQ1M	tachykinin I - mig
24	12 40.0	10 1 ECLQ3M	tachykinin III - m
25	12 40.0	10 2 A43405	6-phosphofructo-2-
26	12 40.0	10 2 A60410	beta-neoendorphin
27	12 40.0	10 2 H60588	sperm-activating p
28	12 40.0	10 2 PT0243	Ig heavy chain CRD
29	12 40.0	10 2 PH1633	Ig H chain V-D-J r
30	12 40.0	10 2 PT0215	T-cell receptor be
31	12 40.0	10 2 PH0944	T-cell receptor be
32	12 40.0	10 2 PH0926	T-cell receptor be
33	12 40.0	10 2 A59173	nuclease Bh1 (EC 3
34	11 36.7	5 1 HOROHA	proctolin - Americ
35	11 36.7	5 2 A60411	proctolin - Atlant
36	11 36.7	6 2 B44510	hypothetical prote
37	11 36.7	7 2 S42407	gramicidin S synth
38	11 36.7	7 2 S78024	ribosomal protein
39	11 36.7	7 2 148105	dihydrofolate redu
40	11 36.7	7 2 I48086	DNA topoisomerase
41	11 36.7	7 2 PD0029	pev-kinin 1 - pena
42	11 36.7	7 4 S15597	orf 4 rara 5'-regi
43	11 36.7	8 2 G33098	205K exoantigen -
44	11 36.7	8 2 \$10783	enamelin f - bovin
45	11 36.7	8 2 A35180	neutral proteinase

ALIGNMENTS

RESULT 1

A32039

tyrosine-melanocyte-stimulating hormone release-inhibiting factor 1 - bovine

C; Species: Bos primigenius taurus (cattle)

C;Date: 31-Jul-1989 #sequence revision 31-Jul-1989 #text change 18-Aug-2000

C; Accession: A32039

R;Horvath, A.; Kastin, A.J.

J. Biol. Chem. 264, 2175-2179, 1989

A;Title: Isolation of tyrosine-melanocyte-stimulating hormone release-inhibiting factor 1 from bovine

brain tissue.

A; Reference number: A32039; MUID: 89123285

A;Accession: A32039 A;Molecule type: protein A;Residues: 1-4 <HOR> A;Experimental source: brain

C; Superfamily: unassigned animal peptides

C;Keywords: amidated carboxyl end

F:4/Modified site: amidated carboxyl end (Gly) #status experimental

Query Match 56.7%; Score 17; DB 2; Length 4; Best Local Similarity 100.0%; Pred. No. 2.8e+05;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 PLG 4

Db 2 PLG 4

Search completed: October 23, 2002, 13:43:51

Job time: 15 secs

OM protein - protein search, using sw model

Run on: October 23, 2002, 13:41:47; Search time 13 Seconds

(without alignments)

13.152 Million cell updates/sec

Title: US-09-808-832-186

Perfect score: 30

Sequence: 1 XPLGXYL 7

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 231628 seqs, 24425594 residues

Total number of hits satisfying chosen parameters: 70601

Minimum DB seq length: 0 Maximum DB seq length: 10

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database: Issued Patents AA:*

1: /cgn2 6/ptodata/1/iaa/5A_COMB.pep:*

2: /cgn2 6/ptodata/1/iaa/5B COMB.pep:*

3: /cgn2 6/ptodata/1/iaa/6A COMB.pep:*

4: /cgn2 6/ptodata/1/iaa/6B COMB.pep:*

5: /cgn2 6/ptodata/1/iaa/PCTUS COMB.pep:*

6: /cgn2 6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%

Result Query

No. Score Match Length DB ID

Description

70.0 8 4 US-08-953-033-7 Sequence 7, Appli 1 21 5 2 US-08-350-260A-321 Sequence 321, App 2 19 63.3 Sequence 80, Appl 19 63.3 6 1 US-08-487-006-80 3 19 63.3 6 2 US-08-488-659A-80 Sequence 80, Appl 4 Sequence 12, Appl 5 18 60.0 6 4 US-09-208-684-12 6 18 60.0 Sequence 24, Appl 6 4 US-09-561-500-24 7 18 60.0 6 4 US-09-561-108-24 Sequence 24, Appl 8 18 60.0 7 1 US-08-340-045-16 Sequence 16, Appl Sequence 136, App 9 18 60.0 7 2 US-08-934-222-136 10 18 60.0 7 2 US-08-933-402-136 Sequence 136, App Sequence 136, App 11 18 60.0 7 2 US-09-207-621-136 Sequence 136, App 60.0 7 2 US-08-532-818-136 12 18 Sequence 16, Appl 60.0 7 3 US-08-871-302A-16 13 18 60.0 Sequence 136, App 14 18 7 3 US-09-231-797-136 60.0 7 3 US-08-934-224-136 Sequence 136, App 15 18 60.0 7 3 US-08-933-843-136 Sequence 136, App 16 18 Sequence 136, App 17 18 60.0 7 4 US-08-934-223-136 60.0 Sequence 136, App 18 18 7 4 US-09-413-492-136 Sequence 2, Appli 19 18 60.0 8 3 US-07-961-307-2 Sequence 16, Appl 20 18 60.0 8 3 US-08-335-865J-16 Sequence 341, App 60.0 8 4 US-08-444-818-341 21 18 Sequence 342, App 60.0 8 4 US-08-444-818-342 22 18 23 18 60.0 8 4 US-08-444-818-343 Sequence 343, App 60.0 Sequence 344, App 24 18 8 4 US-08-444-818-344 60,0 Sequence 2, Appli 25 18 9 2 US-08-585-281-2 26 18 60.0 9 2 US-08-585-281-3 Sequence 3, Appli Sequence 5, Appli 60.0 27 18 9 2 US-08-585-281-5 18 60.0 Sequence 6, Appli 28 9 2 US-08-585-281-6 29 18 60.0 9 3 US-08-159-339A-619 Sequence 619, App 60.0 Sequence 94, Appl 18 10 1 US-08-250-789A-94 30 Sequence 95, Appl 18 60.0 10 1 US-08-250-789A-95 31 32 18 60.0 10 1 US-08-250-789A-96 Sequence 96, Appl 60.0 Sequence 97, Appl 33 18 10 1 US-08-250-789A-97 34 17 56.7 4 1 US-08-219-156-5 Sequence 5, Appli 17 56.7 4 1 US-08-238-089-5 Sequence 5, Appli 35 56.7 Sequence 6, Appli 17 4 1 US-08-238-089-6 36 56.7 Sequence 8, Appli 37 17 4 1 US-08-366-783-8 38 17 56.7 4 1 US-08-432-651A-5 Sequence 5, Appli 39 56.7 4 1 US-08-432-651A-6 Sequence 6, Appli 17 56.7 Sequence 49, Appl 17 4 1 US-08-798-897-49 40 56.7 4 2 US-08-707-237A-97 Sequence 97, Appl 41 17 56.7 42 17 4 2 US-08-978-523-49 Sequence 49, Appl 43 17 56.7 Sequence 11, Appl 4 2 US-08-846-021A-11 44 17 56.7 4 3 US-08-642-246-17 Sequence 17, Appl

ALIGNMENTS

RESULT 1

US-08-953-033-7

; Sequence 7, Application US/08953033

; Patent No. 6165977

GENERAL INFORMATION:

APPLICANT: Mochly-Rosen, Daria

TITLE OF INVENTION: ISOZYME-SPECIFIC ACTIVATORS

TITLE OF INVENTION: OF PROTEIN KINASE C - METHODS AND COM

TITLE OF INVENTION: POSITIONS

NUMBER OF SEQUENCES: 23 CORRESPONDENCE ADDRESS:

ADDRESSEE: Dehlinger & Associates

STREET: 350 Cambridge Ave., Suite 250

CITY: Palo Alto STATE: CA

COUNTRY: USA

ZIP: 94306

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible OPERATING SYSTEM: DOS

SOFTWARE: FastSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/953,033

FILING DATE: 17-OCT-1997 CLASSIFICATION: 530

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/028,724

FILING DATE: 18-OCT-1996

ATTORNEY/AGENT INFORMATION:

NAME: Petithory, Joanne R.

REGISTRATION NUMBER: 42,995

REFERENCE/DOCKET NUMBER: 8600-0174.30

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650-324-0880 TELEFAX: 650-324-0960

TELEX:

; INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:

LENGTH: 8 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

FEATURE:

NAME/KEY: Other LOCATION: 1...8

OTHER INFORMATION: epsilonV1-7.1

US-08-953-033-7

Query Match 70.0%; Score 21; DB 4; Length 8;

Best Local Similarity 60.0%; Pred. No. 1.7e+05;

Matches 3; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 PLGXY 6

111

Db 4 PIGDY 8

Search completed: October 23, 2002, 13:43:30

Job time: 15 secs